TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02040714

Intervention type: PROCEDURE
Intervention: Multiple Epiphyseal Drilling
Description: Multiple epiphyseal drilling is a procedure that creates small holes in the femoral head growth plate to increase blood flow into the femoral head.

Intervention type: PROCEDURE
Intervention: Multiple Epiphyseal Drilling
Description: Multiple epiphyseal drilling is a procedure that creates small holes in the femoral head growth plate to increase blood flow into the femoral head.

Intervention type: PROCEDURE
Intervention: Multiple Epiphyseal Drilling
Description: Multiple epiphyseal drilling is a procedure that creates small holes in the femoral head growth plate to increase blood flow into the femoral head.
Study: NCT00475319

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% OPC-12759 ophthalmic suspension
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% OPC-12759 ophthalmic suspension
Description: comparison of different dosages of drug
Study: NCT00482378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamidronate
Description: 90 mg by IV monthly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 4 mg by IV monthly.
Study: NCT04542681

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - 1st Cycle
Description: Subjects will receive a single SQ injection of placebo/normal saline
Study: NCT00734344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil twice daily
Description: 300mg twice daily
Study: NCT00482378

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sm 153 lexidronam
Description: 0.5 mCi/kg or 1 mCi/kg by IV.
Study: NCT04081792

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic therapy
Description: Postoperative randomizations regarding the duration of systemic antibiotics

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Description: Postoperative randomizations regarding the duration of systemic antibiotics

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic therapy
Description: Postoperative randomizations regarding the duration of systemic antibiotics
Study: NCT03544554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a counseling and training program that consisted of a 45-minute presentation based on Pender's Health Promotion Model. Within the scope of the counseling and training program
Description: The intervention group was provided with a counseling and training program that consisted of a 45-minute presentation based on Pender's Health Promotion Model.
Study: NCT01694420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (FDC) ELV/COBI/FTC/TDF
Description: Antiretroviral treatment
Study: NCT01755195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2).
Study: NCT01682499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium gluconate and magnesium sulfate
Description: Intravenous calcium gluconate and magnesium sulfate, 1g each agent in 100 ml D5W over 30 minutes, immediately before and after each dose of paclitaxel
Study: NCT04470492

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Doctormate®+Medical Management
Description: Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) twice daily and conventional medication for 3 months.

Intervention type: DRUG
Group type: OTHER
Intervention: Medical Management
Description: Patients will be treated with conventional medication for 3 months.
Study: NCT01303380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Study: NCT02689232

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelets Concentrate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelets Concentrate

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cryo Precitipitate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cryo Precitipitate
Study: NCT03279783

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LCI (Linked color imaging)
Description: Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked color imaging)
Study: NCT00093002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 250 mg \& 500 mg intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 250 mg \& 500 mg intramuscular injection
Study: NCT02317406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biostime probiotics sachet children's formula
Description: Biostime probiotics sachet children's formula,1.5g Oral Single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Biostime probiotics sachet children's formula（placebo）
Description: Biostime probiotics sachet children's formula（placebo）,1.5g Oral Single dose
Study: NCT04289454

Intervention type: OTHER
Group type: OTHER
Intervention: Flavor additive
Description: Various flavor additives will be tested (vs. no added flavor) to determine which show promise for making KE drinks taste less unpleasant
Study: NCT01233843

Intervention type: DRUG
Group type: OTHER
Intervention: carboplatin
Description: 70 mg per m2 and per day for four days. day 1; day 22; day 43

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: 70 mg per m2 and per day for four days. day 1; day 22; day 43

Intervention type: DRUG
Group type: OTHER
Intervention: 5 fluorouracil
Description: 600mg per m2 per day for four days. 3 cycles day 1; day 22; day 43

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 fluorouracil
Description: 600mg per m2 per day for four days. 3 cycles day 1; day 22; day 43

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Description: total dose: 70 grays. The patient receives 2 grays per day; five days a week during 7 weeks
Study: NCT03245723

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Function Testing
Description: Subjects will undergo Spirometry and Plethysmography

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pulmonary Function Testing
Description: Subjects will undergo Spirometry and Plethysmography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocardiogram
Description: Subjects will undergo an electrocardiogram to ensure sinus rhythm

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Electrocardiogram
Description: Subjects will undergo an electrocardiogram to ensure sinus rhythm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Subjects will undergo positron emission tomography to detect images of the heart

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Positron Emission Tomography
Description: Subjects will undergo positron emission tomography to detect images of the heart

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Subjects will undergo positron magnetic resonance imaging to detect images of the heart

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Subjects will undergo positron magnetic resonance imaging to detect images of the heart
Study: NCT04081792

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Description: Postoperative randomizations regarding the duration of systemic antibiotics
Study: NCT01233843

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: total dose: 70 grays. The patient receives 2 grays per day; five days a week during 7 weeks
Study: NCT03544359

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial electrical stimulation (tES)
Description: In tES, a mild electrical current is passed between two or more electrodes placed on the volunteer's head (scalp). In this study, a mild unvarying (constant) electrical 2mA current is passed between two rubber electrodes placed on the head over auditory cortex for 20 minutes per session for 5 consecutive days. Because the electrical current direction (positive/negative) and current amplitude (2mA) does not vary or change during stimulation, this type of tES is also called transcranial direct current stimulation, or tDCS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial electrical stimulation (tES)
Description: In tES, a mild electrical current is passed between two or more electrodes placed on the volunteer's head (scalp). In this study, a mild unvarying (constant) electrical 2mA current is passed between two rubber electrodes placed on the head over auditory cortex for 20 minutes per session for 5 consecutive days. Because the electrical current direction (positive/negative) and current amplitude (2mA) does not vary or change during stimulation, this type of tES is also called transcranial direct current stimulation, or tDCS.
Study: NCT01404117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod 0.6
Description: Laquinimod 0.6 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod 1.2
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate or interferon-beta+ Placebo
Description: GA 20 mg/1mL or IFN-B (Avonex®, Betaseron®/Betaferon®, Rebif® or Extavia®) + oral daily placebo
Study: NCT00103402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03119493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Periodized aerobic interval training
Description: The periodized training program consist in 3 phases: light (I) (training range varying between 20 to 39% of heart rate reserve and active recuperation of 19% of heart rate reserve); moderate (II) (training range varying between 40 to 59% of heart rate reserve and active recuperation of 30% of heart rate reserve) and high (III) (training range varying between 70 to 90 % of heart rate reserve and active recuperation of 50% of heart rate reserve).
Study: NCT02655055

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high frequency voluntary apheresis blood donation
Study: NCT02677259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-beta estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Study: NCT04081792

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic therapy
Description: Postoperative randomizations regarding the duration of systemic antibiotics

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Description: Postoperative randomizations regarding the duration of systemic antibiotics

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic therapy
Description: Postoperative randomizations regarding the duration of systemic antibiotics

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Description: Postoperative randomizations regarding the duration of systemic antibiotics
Study: NCT01184508

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally, once daily, for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2300559
Description: 300 milligrams (mg) administered orally, once daily, for 12 weeks
Study: NCT01471392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STD Diagnostic Kit (Identigene)
Description: The Identigene STD Test Collection Kit is an at-home kit that allows individuals to utilize the Gen-Probe technology to test for CT and NG in privacy and in a more convenient manner. The primary technology is the approved Gen-Probe APTIMA Combo 2 assay, which is repackaged into the Identigene kit for use by consumers. As such, the laboratory technology and testing method is identical to that of the Gen-Probe APTIMA Combo 2 assay, which has been cleared for in vitro diagnostic use.
Study: NCT04542681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MANP - 1st Cycle
Description: Subjects will receive a single SQ injection of MANP at a concentration of 2.5 μg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MANP - 2nd Cycle
Description: Subjects will receive a single SQ injection of MANP 5 μg/kg concentration.
Study: NCT02854163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: All eligible patients registered into the study will receive four 150 - 300 mg subcutaneous injections at weekly intervals, followed by regular injections 150mg once a month thereafter for a total of 12 months
Study: NCT02677259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized progesterone
Study: NCT01059721

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medialising insertion of patella tendon
Description: surgical treatment of medialising tibial tuberosity
Study: NCT03629613

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral antioxidant cocktail
Description: Oral antioxidant cocktail intake will occur after baseline measurements:~Dose 1 (immediately after baseline testing): 300 mg alpha-lipoic acid, 500 mg vitamin C, 200 IU vitamin E Dose 2 (30 minutes after Dose 1): 300 mg alpha-lipoic acid, 500 mg vitamin C, 400 IU vitamin E

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Baseline
Description: No oral antioxidant cocktail intake or placebo intake will occur prior to baseline measurements
Study: NCT02378441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg and Metformin SR 750mg
Description: co-administration of Atorvastatin 20mg and Metformin SR 750mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg and Metformin SR 750mg
Description: co-administration of Atorvastatin 20mg and Metformin SR 750mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-30056 20/750mg
Description: fixed-dosed combination of Atorvastatin 20mg and Metformin SR 750mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-30056 20/750mg
Description: fixed-dosed combination of Atorvastatin 20mg and Metformin SR 750mg
Study: NCT02928757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex care clinic as part of the CCKO initiative
Description: The CCKO intervention involves intensive care coordination, defined as: deliberate organization of patient care activities between two or more participants (including the patient) involved in a patient's care to facilitate the appropriate delivery of health care services. Organizing care involves marshaling of personnel and other resources needed to carry out all required patient care activities and is often managed by the exchange of information among participants responsible for different aspects of care. Within CCKO, intensive care coordination will specifically include: 1) the tailored, family/health care provider co-creation and regular updating of care coordination plans for each child which will be 2) facilitated and accounted for by key workers partnering with families.
Study: NCT01436565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121 (SAR256212)
Description: Pharmaceutical form:solution~Route of administration: Intravenous
Study: NCT01809392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: 36 mg/m2 on day 42 after transplantation and administered daily for 5 consecutive days every 28 days for up to a total of 10 cycles
Study: NCT01436565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245408
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT01891305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1161
Study: NCT02219178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 25mg days 1 - 14 of 21 day schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous bortezomib
Description: 1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule
Study: NCT00992173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultratrace Iobenguane I 131
Description: Subjects will receive an Imaging Dose of 0.1 mCi/kg \[3.7 MBq/kg\] (a minimum dose of 1.0 mCi \[37 MBq\] but not to exceed 5.0 mCi \[185 MBq\]) of Ultratrace iobenguane I 131 to have dosimetry performed and to confirm tumor uptake of the test article prior to receiving each of 2 planned Therapeutic Doses of Ultratrace iobeneguane I 131 . Within 28 days of screening, eligible subjects (as confirmed by the first Imaging dose study)will receive an Ultratrace iobenguane I 131 Therapeutic dose of of 15.0 - 18.0 mCi/kg (max. 666 MBq/kg) followed by imaging 7 days later or upon discharge from radiation isolation. A second Therapeutic Dose (preceded by a repeat Image Dose and dosimetry study)and imaging upon discharge from radiation isolation will be repeated approximately 8 weeks after the first dose.
Study: NCT01891305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1161
Study: NCT00566904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epikeia coatings with aspirin
Description: Applied to affected skin area using a roll-on ball applicator
Study: NCT01891305

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01323608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 will be given at the equivalent of the following doses: 400, 1000, and 2000 IU/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 will be given at the equivalent of the following doses: 400, 1000, and 2000 IU/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 will be given at the equivalent of the following doses: 400, 1000, and 2000 IU/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02796456

Intervention type: OTHER
Intervention: blood sample

Intervention type: OTHER
Intervention: blood sample

Intervention type: OTHER
Intervention: blood sample
Study: NCT02196532

Intervention type: DEVICE
Intervention: Device: Optical coherence tomography

Intervention type: DEVICE
Intervention: Device: Optical coherence tomography
Study: NCT04243486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHE-105
Description: Topical shampoo containing active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical shampoo containing no active drug
Study: NCT04353687

Intervention type: DEVICE
Intervention: Robotic-assisted inguinal hernia repair
Description: Each surgeon will perform the robotic-assisted inguinal hernia procedure per their standard practice. Surgeon subjects will consent to prospectively provide selected procedure and case data.

Intervention type: DEVICE
Intervention: Robotic-assisted inguinal hernia repair
Description: Each surgeon will perform the robotic-assisted inguinal hernia procedure per their standard practice. Surgeon subjects will consent to prospectively provide selected procedure and case data.
Study: NCT03981276

Intervention type: OTHER
Intervention: Clinical rating scale to measure disease severity and progression
Description: A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.

Intervention type: DIAGNOSTIC_TEST
Intervention: Next-Gen Sequencing (NGS)
Description: Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
Study: NCT00566904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epikeia coatings with lidocaine
Description: Applied to affected skin area using a roll-on ball applicator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epikeia coatings alone
Description: Applied to affected skin area using a roll-on ball applicator
Study: NCT03981276

Intervention type: DIAGNOSTIC_TEST
Intervention: Next-Gen Sequencing (NGS)
Description: Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics

Intervention type: DIAGNOSTIC_TEST
Intervention: Next-Gen Sequencing (NGS)
Description: Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
Study: NCT03641287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Counseling
Description: Meet with exercise physiology

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Receive prescription for moderate aerobic exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological Support
Description: Receive motivational support via telephone care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo habitual level of physical activity
Study: NCT02398019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OXIRIS®
Description: OXIRIS® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication \[OXIRIS® (Baxter Gambro)\].~PrismafleX eXeed™ II (Hospal) with OXIRIS® set will then be connected to CPB circuit. Blood flow between 150-200 ml/min will be derivatised from the CPB circuit into the PrismafleX eXeed™ so that it all flows through OXIRIS® membrane. Flow, pressure and alarms will be controlled by PrismafleX eXeed™ independently from CPB circuit.~OXIRIS® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time.
Study: NCT01668680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPECITABINE, CELECOXIB and METHOTREXATE
Description: daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE
Study: NCT00557193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Given IV, IM, or PO